Avanos Medical(AVNS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported full year net sales of $701 million, exceeding the revised guidance range following Q3 [4] - Adjusted diluted earnings per share for the year was $0.94, finishing at the high end of the earnings guidance range [4] - For Q4, net sales were approximately $181 million, with adjusted diluted earnings per share of $0.29 and adjusted EBITDA of $28 million [11] Business Line Data and Key Metrics Changes - Specialty Nutrition Systems portfolio grew over 8% organically compared to the prior year, with strong demand for long-term enteral feeding products [6][15] - The short-term enteral feeding portfolio posted double-digit organic growth globally, driven by the U.S. CORTRAK offering [7][15] - Pain Management & Recovery portfolio saw normalized organic sales up 2.3%, with the radiofrequency ablation business delivering double-digit organic growth [8][16] Market Data and Key Metrics Changes - The neonatal solutions business delivered above-market performance, growing over 6% compared to the prior year [15] - The company experienced sustained growth in its RFA generator capital sales, contributing to above-market growth [8][16] - The surgical pain business was down year-over-year due to delays in the implementation of the NOPAIN Act [9][16] Company Strategy and Development Direction - The company is focused on five strategic imperatives: accelerating organic growth, managing tariff impacts, realizing operating efficiencies, improving or divesting underperforming assets, and acquiring synergistic businesses [10] - The company is executing a China exit strategy, aiming to have all syringe manufacturing operations out of China by June 2026 [12][21] - The integration of Nexus Medical into the neonatal portfolio is progressing well, with expectations for continued double-digit growth [13][15] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued mid-single-digit organic sales growth in strategic segments for 2026, despite expected tariff expenses [19] - The company expects gross margin improvement to begin in the second half of 2026, following tariff mitigation strategies [20][34] - Management expressed confidence in the company's position for continued growth and the execution of strategic imperatives [23] Other Important Information - The company generated $43 million of free cash flow for the full year, higher than anticipated [19] - The balance sheet remains strong with $90 million in cash and $100 million in debt as of December 31 [18] - The company expects capital expenditures in the range of $25 million for 2026, slightly lower than 2025 [22] Q&A Session Summary Question: Insights on tariffs and 2026 outlook - Management estimates a $30 million impact from tariffs in 2026, with a significant portion related to China [27][29] - The company is confident in exiting China by June and delivering products from Mexico and Cambodia [28] Question: Revenue guidance and organic growth rates - The consolidated organic growth rate is expected to be around 5%, with mid to high single digits for Specialty Nutrition Systems and low to mid single digits for Pain Management & Recovery [37] Question: Operating leverage and cost-saving initiatives - Management is confident in continuing to drive efficiency in 2026, with a focus on both R&D and SG&A [38][39] - Cost containment measures are expected to offset additional tariff expenses [42] Question: Performance of Specialty Nutrition Systems and Nexus - Demand for the Specialty Nutrition Systems portfolio remains high, with Nexus performing better than expected [44][45]